The incorporation of NT-proBNP into the multivariate base prediction model promoted a 39% increase in the net reclassification index for 5-year cardiovascular risk prediction among T2DM patients enrolled in the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Evaluation) trial [64]. This evidence concerns the gene NPPB and type 2 diabetes mellitus.